Getinge Receives CE Mark for Cardiohelp II ECLS System and EU MDR Approval for Intergard Synergy Vascular Graft

Key Takeaways

• Getinge’s next-generation Cardiohelp II ECLS system receives CE mark approval for European market launch
• Intergard Synergy antimicrobial vascular graft gains EU MDR approval for cardiovascular surgery applications
• Regulatory approvals position Getinge to expand market presence in critical care and cardiovascular device segments

---

Getinge Achieves Dual Regulatory Wins in Q1 2026

Getinge AB announced significant regulatory achievements in its first quarter 2026 interim report, securing CE mark approval for its Cardiohelp II extracorporeal life support (ECLS) system and EU Medical Device Regulation (MDR) approval for the Intergard Synergy antimicrobial vascular graft.

Cardiohelp II Represents Next-Generation ECLS Technology

The CE mark approval for Cardiohelp II marks a pivotal moment for Getinge’s critical care portfolio. This next-generation ECLS system was developed through extensive collaboration with healthcare customers to address evolving clinical needs in extracorporeal membrane oxygenation (ECMO) therapy.

ECLS systems provide temporary cardiac and respiratory support for critically ill patients, particularly those with severe heart or lung failure. The Cardiohelp II system builds upon Getinge’s established presence in the ECMO market, offering enhanced features designed to improve patient outcomes and clinical workflow efficiency.

Cardiovascular Portfolio Strengthened with Intergard Synergy Approval

Simultaneously, Getinge received EU MDR approval for its Intergard Synergy antimicrobial vascular graft, expanding treatment options for cardiovascular surgery procedures. This approval demonstrates the company’s commitment to addressing infection prevention in vascular interventions, a critical concern in cardiovascular surgery.

The EU MDR represents Europe’s stringent medical device regulatory framework, making this approval particularly significant for market access across European Union member states.

Market Impact and Strategic Positioning

These regulatory milestones strengthen Getinge’s competitive position in two high-growth medical device segments. The global ECMO market continues expanding due to increasing critical care needs, while antimicrobial medical devices address growing concerns about healthcare-associated infections.

Getinge’s Q1 2026 report highlighted organic growth and strong cash flow alongside these regulatory achievements, suggesting robust operational performance supporting continued innovation investments. The company’s ability to secure approvals for advanced medical technologies reinforces its research and development capabilities in life-critical healthcare solutions.

---

Frequently Asked Questions

What is the Cardiohelp II ECLS system used for?

The Cardiohelp II is an extracorporeal life support system that provides temporary heart and lung support for critically ill patients with severe cardiac or respiratory failure, commonly used in ECMO therapy.

When will these devices be available in Europe?

With CE mark and EU MDR approvals now secured, both the Cardiohelp II ECLS system and Intergard Synergy vascular graft can be marketed and sold across European Union member states, though specific launch timelines depend on Getinge’s commercial strategy.

How significant are these approvals for Getinge’s business?

These approvals are highly significant as they enable Getinge to compete in growing medical device markets - critical care ECMO systems and antimicrobial cardiovascular devices - while demonstrating the company’s innovation capabilities in life-critical healthcare technologies.

Related coverage

• From Approval to Access: Europe’s Next Health Imperative for Pharma
• Hayes Receives 2026 ESMO Breast Cancer Award: Key Insights
• CinnaGen's Zandoriah Achieves EU Approval for Osteoporosis Treatment